diagnost tool
diagnost tool
price close busi juli
volum outlook sedivu sdma slide
look bright remain top pick
recent sent proprietari survey vet across collect
respons check posit look stock trade higher
new product sdma-on-a-slid sedivu snap fecal come
geograph expans competit win lab test risen nice post
news zts-abax merger analyst day continu like
appreci abaxi new product launch rapid test vetscan urin
sediment analyz concern combin zts-abax relat
given breadth experi global commerci juggernaut
remain top pick rais pt reiter buy
pt expect soon complet acquisit abax
vet volum outlook hot vet survey expect practic volum growth
y/i last two survey expect healthi robust growth
defin growth higher y/i vs prior survey
sedivu saw nice spike vet purchas sedivu record
nice last three survey anoth
expect order next one two year respect remain seen
convert familiar said certain
sdma-on-a-slid nice april vet survey
order sdma-on-a-slid sinc launch januari awar sdma vs
last quarter interpret sdma result vs last quarter
knew launch sdma-on-a-slid expect sdma test lab
in-clin combin result idexx launch sdma in-clin
found adopt abax new product look littl impact
least near term
abax flex four vet survey order abax flex rapid test
anoth expect order year total first year launch
peg rev first year launch base multiplex
rapid test lower estim heard rev year
anoth expect buy within two year remain seen abax convert
familiar said certain
abax sediment analyz sa vet survey order abax new sa
last survey anoth expect order later year anoth
would like buy within two year remain seen abax convert
familiar said certain
refer lab share neck-and-neck vet indic use lab
provid vs use woof believ well posit continu take
share woof climb nearli point share octob
survey past month
thought ahead result remain buyer
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
volum outlook sedivu sdma-on-a
slide look bright remain
top pick rais pt buy
recent sent proprietari re-vamp survey veterinarian across
unit state collect respons check suggest on-going confid
vet patient volum growth rise awar uptak new product
launch mainli come away clear winner
survey result in-clin sdma test sedivu show higher adopt
quarter survey think could mark upsid estim
continu keep eye abax rapid test launch ahead
compani merger zoeti laid number impress near-term
product launch long-term financi target look evid execut
updat ou strategi view remain anim health market
zero-sum game floor limit given strong
trend scarciti valu space reiter hold abax pt
buy rate pt rais price target
use multipl unchang adj
ep estim updat estim
abax note
question data point survey weve ask
expect vet practic revenu growth
expect around plans/likelihood switch brand in-clin chemistri
hematolog rapid test refer lab
actual level switch clinic in-clin chemistri hematolog rapid
test refer lab trail quarter
veterinarian percept top diagnost compani categori
veterinarian adopt idxx sedivu instrument
veterinarian awar adopt idxx novel sdma test
veterinarian awar adopt abax rapid test
veterinarian awar adopt abax new sediment analyz sa
top five survey takeaway
survey suggest continu uptak idxx sdma-on-a-slid test
vet survey alreadi order idxx new sdma-on-a-slid test
expect order april vet
awar new sdma-on-a-slid launch april view
extrem high awar new product launch vet expect
sdma test aggreg result idxx sdma-on-a-slid launch
inclus sdma send-out slide test vet awar idxx
sdma test april survey outstand view
sedivu uptak mark bright spot vet survey
purchas idxx sedivu instrument urin sediment record nice
diagnost tool
last three survey vet unfamiliar
sedivu vs april decemb
underli anim health market remain healthi vet outlook market
growth strong line think vet survey expect
practic volum growth y/i vs april decemb
expect healthi robust growth defin growth higher y/i vs
prior two survey expect strong growth defin
growth higher y/i vs prior two survey
abax rapid test written though await evid
adopt vet survey use handheld snap rapid test
practic vs abax compar
abax april declin gain abax survey
indic vet unfamiliar abax rapid test vs
april survey mark slight posit abax remain seen
abax convert indic survey
familiar abax flex certain
competit swap-out refer lab in-clin chemistri hematolog
well rapid test appear limit suggest stabl market share
believ posit industri leader uncov modest
adopt abax new product rapid test vetscan urin sediment
analyz posit abax think impact may minim
thought print
dive detail survey offer preview result
buy-rat hold-rat abaxi
abax set report result wednesday august set
report tuesday august hold earn call
et respect expect abax report quarterli result
host earn call abax sharehold vote schedul juli
expect zts/abax merger close like august shortli thereaft
big pictur view believ well posit benefit
meaning new product launch geograph expans competit
win notabl refer lab newly-announc us salesforc
expans take sale forc end
think move part respons zts/abax merger believ new product
launch sdma-on-a-slid sedivu come earli snap fecal
antigen like propel solid double-digit revenu growth
idexx model revenu y/i line
consensu adj ep y/i vs consensu look
gm om vs street expect
consum servic revenu y/i refer lab
revenu y/i rapid assay revenu y/i
instrument revenu y/i expect place y/i
sedivu analyz record y/i
out-performance either
core new product think may upsid idxx revenu guidanc
organ adj ep
model revenu adj ep
diagnost tool
thought print like recent larg new custom
win new product launch scarciti valu last stand
small pure-play anim health diagnost compani wake zts-abax deal
announc narrowli trim expect level-set pace
quarter believ de-risk near-term setup analyst day may
continu like new product launch also given
scarciti valu thesi anim health said shouldnt layup
face juggernaut solid improv abax opinion
analyst day may moder low bar baselin
revenu trim revenu guid due
ovp initi quarterli revenu target balanc expect
gm flat full year revenue growth blood consum
imag partial off-set ovp
provid expect quarterli cadenc assum sequenti
declin revenu follow acceler back half
expect revenu vs prior analyst
day vs prior vs prior
om includ hska
revenu growth target consum growth subscript
market share growth digit imag ovp revenu
ovp segment expect expens higher
y/i expens higher expens higher compar
model in-lin revenu y/i ep
vs street delta our/street estim due
expect around opex look companion anim health cca
revenu y/i vs street vaccin
pharma ovp revenu y/i look gm om
vs street
recent announc pend merger vet first
choic form vet first corp upon close think may prove logic
compani fold newco recal exclus distributor
still search ou partner also think mar inc would logic
interest buyer bidder
thought abax expect zts-abax deal close earli earli august
certainli end view strong outcom abax sharehold
help abax meaning expand ou better compet
howev believ overcom competit impact given market-
lead posit first-mov advantag ou diagnost deep breadth
offer abax tabl believ even greater scarciti
valu potenti subject bid war mar inc henri
schein expect remain market leader anim diagnost
year come ltm revenu vs abax expect abax/zt
becom formid ou togeth
expect abax earn call model revenu
vs street model adj ep y/i vs
street attach financi model back note
diagnost tool
takeaway latest survey
survey suggest vet awar rise idxx sdma-on-a-slid test
vet familiar idxx sdma test april survey
line decemb survey vet awar
move sdma in-clin catalyst dx instrument
april decemb vet indic order
sdma-on-a-slid test idexx catalyst instrument vs april
expect order vs april
figur survey suggest rise awar sdma-on-a-slid in-clin avail
state march investor confer north american
catalyst custom alreadi purchas sdma-on-a-slid vet
survey indic expect sdma test result move
sdma in-clin versu decemb vet survey indic
theyv interpret sdma result peg sdma sedivu
increment opportun respect
anoth success test move lab clinic total
test thyroid achiev clinic order end
first year alreadi taken order practic america alon
februari translat one-third american catalyst
instal base indic sdma add-on ad
clip chemistri panel expect drive
revenue/year sdma think may prove conserv
also launch catalyst sdma uk ireland late march
expect addit countri launch throughout expect
cannib test lab consist experi
year launch hold ip reagent method
detect sdma expir accord competitor want
offer sdma would work around idxx intellectu properti
remind work partner yale univers
complet valid sdma use human earli call think
opportun like human partner bring novel sdma
test human diagnost market think year away think
logic partner would includ abbott roch name two
idxx sedivu steadili progress vet survey purchas
sedivu vs april decemb june
oct anoth expect order within year vs april
decemb june oct vet
unfamiliar sedivu april decemb
addit vet survey indic theyr form urinalysi
diagnost tool
test either in-clin send vs april survey
decemb survey june survey oct survey
indic could urinalysi test easier vs
april survey decemb survey vet agre urin
analyz within hour time collect remain seen
convert familiar said
certain furthermor vet indic sedivu clinic valuabl
vs april decemb june
continu believ may convert market time
assum impli penetr rate vet clinic us
data suggest clinic could potenti adopt sedivu time
feb launch sedivu neural network sedivu
come strong sedivu quarter easili
top expect unit think may see inflect
sedivu year rel pictur place
sedivu less catalyst instal base thu see year
runway ahead sedivu estim placement
opportun sedivu
figur percentag vet order sedivu trend last four survey vet unawar decreas
survey comment respond idxx sedivu includ
busi clinic twice daili lab pick-up get result
hour sedivu concern would take much tech time
know order interest discuss
may worthwhil current model send urin sampl
evalu anyway
sent worth time staff analyz
neat toy expens
enough revenu price
diagnost tool
vet growth outlook remain strong in-lin expect
vet expect practic volum growth y/i april
survey decemb survey expect healthi robust
growth defin growth higher y/i vs prior two
survey degre eas moder prior concern util
might slow clinic
figur vet expect patient volum practic revenu grow higher y/i
vet expect growth hover y/i expect robust growth
y/i vs april survey
decemb survey data suggest uptrend percentag vet
expect posit growth y/i percentag vet expect growth
healthi acknowledg survey popul
think data bear watch go forward
weight averag y/i market growth expect came vs
april decemb june continu
expect practic revenu growth vet clinic support low single-digit
volum growth price gain new sourc product revenu
figur vet character volum practic revenu healthi robust
diagnost tool
chemistri instrument market share juli came
abax noth respect in-clin chemistri
instrument vs april vs
decemb june
direct posit neg
acknowledg survey sampl size look popul
in-clin hematolog instrument market share came
abax noth respect vs
april vs decemb
june come winner survey
market share data deliv high r-squar life
anim survey expect modest level variat survey due
small sampl size refer lab found
vca/mar versu vca/mar april survey
refer lab data past five survey sinc oct suggest
narrow market share climb point
vca/mar declin point
figur in-clin chemistri market share steadi time though look
bit lighter recent period seek win market share gain year
canaccord genuiti survey data includ data juli well prior survey period note
figur market share statist remain gener rang slight variat
attribut small sampl size
diagnost tool
level brand switch remain key trend believ favor
market leader vet survey recent switch in-hous
chemistri instrument analyz within last month bracket april
decemb survey none vet survey switch extern
refer lab within past three month in-lin
april survey decemb survey switch rapid test
hematolog brand last month expect switch rapid test provid
next year in-lin april survey
prior dec june survey
vet survey use extern refer lab provid
year vs april survey refer lab util found
vca/mar larg mirror april result
vca/mar mark lead-chang decemb
result vca/mar refer lab data
past five survey sinc oct suggest narrow market share
climb point vca/mar declin
point
continu domin percept survey fourth time
ask vet rank percept key brand best-of-bre broad
rang product knowledg help sale rep time help
custom servic highli accur test result abax easy-to-us
product fair price
gain point knowledg help sale rep past
four survey sinc june testimoni invest made
improv direct sale channel doubl sale forc
 america sinc june announc plan expand
rep end recal began train compens
us-bas sale rep new econom valu late goal
align sale forc focu top profit contributor
base expect seven-year annuiti sale encourag
earli sign improv align product grow salesforc
surpris see win offer broad rang product
fourth survey row given idxx clear market leadership vet instrument
consum softwar surpris percept
survey vet gave nod categori gain point
past month believ contempl
custom appreci uptak new product launch like sdma
despit appar pushback idxx higher price rel peer
continu win sever percept categori track notabl
vet consid best breed vs april decemb
june survey believ affirm idxx leadership posit think
recent innov idxx sdma-on-a-slid might posit impact
best breed question compani offer
diagnost tool
figur domin percept survey wide rang categori
record vet indic abax offer easy-to-us product vs
april decemb june abax also offer fair price
vs regard offer broad rang
product abax gain point past four survey month
attribut new product launch vetscan sa urin sediment analyz
rapid test etc respond consid abax best breed mark
steadi improv prior survey jump june
result believ support point improv accur test
result easy-to-us product offer broad rang product fair price
past four survey came last place highli accur result easy-
rep broad rang product best breed saw signific
improv offer broad rang product came vs
april june recal announc analyst day may intent
launch element urin sediment analyz element immuno-diagnost
analyz element fecal imag analyz peg
target launch
respect think signific new product
without competit market leader abaxi smallest
three compani survey respons surpris us much
particularli realli good compani abax
figur abax shown steadi improv number categori though custom
servic help rep categori remain depress compar
diagnost tool
figur shown improv offer broad rang product though continu
face challeng smallest competitor oligopolist market
figur everi categori except ease-of-us fair price
command strong posit rapid test though abax see signific
jump usag vet juli survey indic use
handheld snap rapid test practic vs abax
compar april survey
show slight declin gain abax attribut
larg discrep natur variat given small sampl size
coupl sign earli traction abax rapid test launch
vet juli survey indic order abax flex
rapid test alreadi anoth indic like order year
suggest market may adopt flex four year launch
anoth indic would like buy within year suggest
adopt within year launch result show slight declin
april result indic vet order could
potenti adopt within year read slight variat
consid result small sampl size continu believ abax pose
competit idxx snap line first four quarter launch
survey suggest abax could drive revenu first year
launch assum point standard deviat bar base
million multiplex rapid test frankli estim
folk weve heard think abax could revenu
first year launch
survey indic vet unfamiliar abax rapid
test vs april survey mark slight posit abax remain
seen abax convert indic survey
familiar abax flex certain
diagnost tool
vet indic like littl chanc switch
rapid test brand mark slight uptick april survey
lowest level seen past four survey vet
decemb june indic unlik switch rapid test
abax indic call saw nice initi stock order
distributor patterson mwi name three rapid price
industri leader abax drove y/i growth rapid assay
revenu note distributor feedback outstand despit
abax decis lower margin unclear much rapid
segment revenu revenu snap
estim one industri expert talk opin
abax bolt revenu within year abax expect
sell everyth manufactur near term think abax
could deliv revenu june quarter
technolog believ superior abax later flow technolog
fulli expect see side-bi side studi compar idxx test vs abax
becom commerci avail dismiss abax
test challeng given abax market test cheaper
accur altern requir fewer user step think
hold key differenti snap system automat activ
interpret snap test result connect idxx softwar system
figur saw slight bounc record low april survey
abaxi sediment analyz directli compet idxx sedivu wait
evid vet adopt base juli survey vet indic
order abax new sediment analyz anoth indic
theyr like order later year anoth indic would like buy
within year remain seen abax convert
familiar product said certain abax
deliv solid vetscan sediment analyz abbrevi
partial quarter result gener revenu impli
abax look captur high
gm consum
abax like plan sell sa around list price
abax vetscan sa use consum roughli price per run
substanti high gm abax sa significantli smaller footprint
last year manag optimist sa make strong impact
put abax sa perspect year averag unit sold per
quarter first year launch averag
instrument sold per quarter estim sell instrument
diagnost tool
approxim would impli approxim run-
rate capit place sedivu
assum abax achiev success realiz
assum grow sediment urin market estim abax could place
vetscan sediment analyz sa first four quarter launch
would impli sold capit capit revenu first four
quarter abax model assum sa sold given
aforement assumpt model could conserv system
revenu said abax indic us would will go
reagent rental sa that case would forego up-front capit
collect period year think
veterinari pharmacy/ prescript manag provid util roughli
vet clinic accord data ask veterinarian brand
pharmacy/prescript management/hom deliveri pharmaci provid clinic
use today result show survey vet use either vet
first choic vetsourc expect grow number clinic
like turn third-parti vendor like vet first choic vet look
grow pharmaci therapeut food revenu lower inventori increas patient
adher therapi identifi new gap patient care remind
earlier year agre merg vet first choic renam
compani vet first corp
conclus survey work
innov remain ripe anim health diagnost industri support
strong macro backdrop rich strong underli growth trend highest
level veterinarian percept market growth come
past four survey line expect
appear year mark sever new product launch product
extens three major anim health competitor feel reflect
percept survey data past four survey month abax
gain point offer broad rang product
categori sinc first percept survey june
juli survey bode well idxx execut new product awar
uptak sdma sedivu shown upward trend past
month survey work last year accur predict
showcas idxx market leadership expect continu year come
given global leadership posit solid visibl high-margin
recur busi double-digit bottom line adj ep growth survey continu
show low level swap-out think benefit industri leader
histor retain custom consist domin
percept survey improv upon everi measur metric except fair
price sinc first includ question june survey assign
higher multipl stock follow announc plan increas
us sale forc end come littl
surpris us sinc continu refin improv busi think
move part respons zts/abax merger although indic us
contempl plan prior zts/abax deal
diagnost tool
abaxi zoeti may announc definit merger agreement
zoeti acquir abaxi enterpris valu deal
receiv ftc anti-trust clearanc earli juli think lot learn sell
diagnost think take time compani catch
expertis term headcount employ rep ou target rep
world-wide compar us ou said
zoeti hope on-board abaxi sale peopl upon deal close
consid juli survey posit abaxi vet awar rapid test
improv abax gain point rapid test usag declin
point given earli natur launch abax vetscan urin sediment analyz
await evid pose materi threat idxx sedivu
remain smallest anim diagnost compani univers look
carv market share year receiv number solid updat
heska analyst day may highlight major new product launch come
growth margin target addit visibl
intern expans plan stock risen low
earli februari current level posit hska
revenu target impli compound-annual-growth-rate gm target om
target mark upsid saw
await sign execut new product launch sign traction larger
us salesforc clariti surround expans outsid north america
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
canaccord genuiti estim compani report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
